Sugi Predict

Sugi Predict / Targets / PFDN2

PFDN2

Prefoldin subunit 2 · Q9UHV9 · PFDN2 on Sugi Atlas →

0 patent compounds predicted against PFDN2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to PFDN2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Ketamine Treatment Effects on Synaptic Plasticity in Depression PHASE4COMPLETED
Treatment of Ectopic Calcification in Fahr's Disease or Syndrome PHASE2RECRUITING
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy. PHASE1/PHASE2RECRUITING
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors PHASE1COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors PHASE1COMPLETED
Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy EARLY_PHASE1RECRUITING
Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D) EARLY_PHASE1COMPLETED
Measuring Protein Turnover in Humans Across the Lifespan by Metabolic Labeling With Deuterium Oxide nanRECRUITING
Mapping Novel Disease Genes for Dilated Cardiomyopathy nanCOMPLETED
A Comparison of Rapid Immunoassay Tests for the Detection of Ruptured Membranes nanWITHDRAWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Implementation of Molecular Diagnostic Pathways nanUNKNOWN
Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia nanRECRUITING
Muscle Tissue Bank for Muscular Dystrophy nanCOMPLETED
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq) nanRECRUITING
Identification of New FTLD Genes nanUNKNOWN
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
Investigations Into ISCU Myopathy or Iron Sulfur Scaffold U Protein Myopathy nanCOMPLETED
Gene Analysis of Parkinson's Disease nanCOMPLETED
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH) nanCOMPLETED
Signs and Symptoms of Genetic Abnormalities Linked to Inherited Heart Disease nanCOMPLETED
Genetic Determinants of Exercise-Induced Muscle Damage (POLYGENDOMUS) nanRECRUITING
3D-Microscopic Muscle Architecture in Cerebral Palsy nanRECRUITING
Transcranial Magnetic Stimulation (TMS) Studies of Dystonia nanCOMPLETED
Amyotrophic Lateral Sclerosis (ALS) Families Project nanRECRUITING
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic nanCOMPLETED
C-Protein in Fatigue and Aging nanRECRUITING
Proteomic Profiling to Reveal Novel Prognostic Markers for Neurological Outcome Following Resuscitation nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PFDN2 binder may also engage these)

ProteinNameSimilarity
B0BN18 — 1.000 B0BN18 →
O70591 — 1.000 O70591 →
A1A4P5 — 1.000 A1A4P5 →
Q9JHS4 — 0.940 Q9JHS4 →
Q4SPU8 — 0.938 Q4SPU8 →
Q5R7N3 — 0.938 Q5R7N3 →
Q5D016 — 0.936 Q5D016 →
CLPX ATP-dependent clpX-like chaperone, mitochondrial 0.936 landscape →
Q5U2U0 — 0.934 Q5U2U0 →
Q5ZLF0 — 0.930 Q5ZLF0 →
P50503 — 0.929 P50503 →
Q5R601 — 0.925 Q5R601 →
Q9QY76 — 0.924 Q9QY76 →
P80584 — 0.924 P80584 →
Q63525 — 0.924 Q63525 →
O04350 — 0.923 O04350 →
Q6PEC1 — 0.923 Q6PEC1 →
Q91858 — 0.923 Q91858 →
Q66HR2 — 0.923 Q66HR2 →
Q61166 — 0.923 Q61166 →
Q08AG7 — 0.922 Q08AG7 →
P37285 — 0.922 P37285 →
Q9Z269 — 0.922 Q9Z269 →
Q2U002 — 0.922 Q2U002 →
Q80TY0 — 0.922 Q80TY0 →
O35685 — 0.922 O35685 →
Q6P848 — 0.922 Q6P848 →
PPME1 Protein phosphatase methylesterase 1 0.921 landscape →
Q9Z270 — 0.921 Q9Z270 →
Q3ZBD9 — 0.921 Q3ZBD9 →